Advanced search
Publication Cover
Modern Rheumatology Volume 24, 2014 - Issue 2
Journal homepage
257
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Efficacy and safety of reducing duration of infliximab infusion

Shunsuke FukuyoThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Kazuyoshi SaitoThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Kunihiro YamaokaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Norifumi SawamukaiThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Shintaro HirataThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Masao NawataThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Shigeru IwataThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
&
Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JapanCorrespondence[email protected]
 show all
Pages 275-280 | Received 11 Jan 2013, Accepted 16 Apr 2013, Published online: 11 Oct 2013

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

HM Lindegaard, P Johansen, G Gröndal, EC Jensen, L Juul, AM Schlemmer, B Agular & IMJ Hansen. (2016) Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious. Scandinavian Journal of Rheumatology 45:4, pages 262-266.
Read now

Articles from other publishers (3)

Andreas Stallmach, Andreas Sturm, Irina Blumenstein, Ulf Helwig, Sibylle Koletzko, Petra Lynen, Carsten Schmidt, Axel Dignass & Torsten Kucharzik. (2020) Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Zeitschrift für Gastroenterologie 58:10, pages 982-1002.
Crossref
Andreas Stallmach, Andreas Sturm, Irina Blumenstein, Ulf Helwig, Sibylle Koletzko, Petra Lynen, Carsten Schmidt, Axel Dignaß & Torsten Kucharzik. (2020) Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie – offene Fragen und Antworten. Zeitschrift für Gastroenterologie 58:07, pages 672-692.
Crossref
Lev Lichtenstein, Yulia Ron, Shmuel Kivity, Shomron Ben-Horin, Eran Israeli, Gerald M. Fraser, Iris Dotan, Yehuda Chowers, Ronit Confino-Cohen & Batia Weiss. (2015) Infliximab-Related Infusion Reactions: Systematic Review. Journal of Crohn's and Colitis 9:9, pages 806-815.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.